 SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 GLOBE NEWSWIRE -- Harpoon Therapeutics, Inc. Nasdaq: HARP, a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it has commenced an underwritten public offering of its common stock. In connection with the offering, Harpoon Therapeutics intends to grant the underwriters in the offering a 30-day option to purchase up to an additional 15 percent of the number of shares sold. 